

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

**POLL RESULTS OF 2018 ANNUAL GENERAL MEETING
HELD ON JUNE 27, 2019;
APPOINTMENT OF MEMBERS FOR THE FOURTH SESSION OF
THE BOARD AND SUPERVISORY COMMITTEE;
APPOINTMENT OF CHAIRMAN FOR THE FOURTH SESSION OF
THE BOARD AND CHAIRMAN FOR THE FOURTH SESSION OF
THE SUPERVISORY COMMITTEE;
AND
APPOINTMENT OF MEMBER / CHAIRMAN OF THE BOARD
COMMITTEES**

The Board is pleased to announce that all resolutions set out in the Notice of AGM were duly passed at the AGM held on June 27, 2019.

THE POLL RESULTS OF ANNUAL GENERAL MEETING

References are made to the notice of AGM of the Company dated May 10, 2019 and the supplemental notice of AGM of the Company dated June 12, 2019 (collectively, the “**Notices of AGM**”), the circular of the Company (the “**Circular**”) dated June 4, 2019 and the announcement of the Company (the “**Announcement**”) dated June 6, 2019. Unless otherwise indicated, capitalised terms used herein shall have the same meanings as those defined in the Circular or the Announcement.

The Board is pleased to announce that the AGM was held at 10:00 a.m., on Thursday, June 27, 2019 at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, PRC, by way of an on-site meeting, and all resolutions set out in the Notices of AGM were passed by way of poll. Computershare Hong Kong Investor Services Limited, the Company’s H share registrar, was appointed as the scrutineer for the vote-taking at the AGM.

The meeting was convened by the Board and chaired by Dr. Hou Yongtai, the chairman of the Board.

As at the date of the AGM, the total number of Shares issued by the Company was 160,045,300 Shares, comprising 120,000,000 Domestic Shares and 40,045,300 H Shares, which was the total number of Shares entitling the Shareholders of the Company to attend and vote for or against or abstain from voting in respect of the resolutions proposed at the AGM. Shareholders holding an aggregate of 134,408,457 Shares with voting rights, representing approximately 83.982% of the total issued Shares, attended the AGM either in person or by proxy. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules and no Shareholder was required under the Listing Rules to abstain from voting at the AGM. There was no restriction on any Shareholders to cast votes on any of the proposed resolutions at the AGM. None of the Shareholders have stated their intention in the Circular or Announcement to vote against or to abstain from voting on the resolutions proposed at the AGM.

The poll results of the AGM were as follows:

Ordinary Resolutions ⁽¹⁾		Number of Votes (%)		
		For	Against	Abstain ⁽²⁾
1	To approve the work report of board of directors of the Company (the “ Board ”) for 2018.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
2	To approve the work report of supervisory committee of the Company (the “ Supervisory Committee ”) for 2018.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
3	To approve the financial reports of the Company for 2018.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
4	To approve the appointments of Ernst & Young Hua Ming LLP and Ernst & Young as the Company’s domestic and international auditors, respectively, until the close of the annual general meeting of the Company for 2019, and to authorise the Board to fix their respective remunerations.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
5	To approve the proposal on the election of directors for the Fourth Session of the Board.			
5.1	To elect Dr. Hou Yongtai as an executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	129,673,403 (96.822604%)	4,255,450 (3.177396%)	479,604 (—)

Ordinary Resolutions ⁽¹⁾		Number of Votes (%)		
		For	Against	Abstain ⁽²⁾
5.2	To elect Mr. Wu Jianying as an executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	129,367,533 (96.252198%)	5,037,224 (3.747802%)	3,700 (—)
5.3	To elect Mr. Huang Ming as an executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	129,200,203 (96.127701%)	5,204,554 (3.872299%)	3,700 (—)
5.4	To elect Ms. Chen Yiyi as an executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	130,590,207 (97.161894%)	3,814,550 (2.838106%)	3,700 (—)
5.5	To elect Mr. Tang Minjie as an executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	130,588,707 (97.160778%)	3,816,050 (2.839222%)	3,700 (—)
5.6	To elect Ms. You Jie as a non-executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	129,340,833 (96.232333%)	5,063,924 (3.767667%)	3,700 (—)
5.7	To elect Mr. Chen Huabin as an independent non-executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	132,864,157 (99.142326%)	1,149,400 (0.857674%)	3,700 (—)
5.8	To elect Mr. Shen Hongbo as an independent non-executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	132,673,857 (99.000325%)	1,339,700 (0.999675%)	3,700 (—)
5.9	To elect Mr. Zhu Qin as an independent non-executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	132,864,157 (99.142326%)	1,149,400 (0.857674%)	3,700 (—)
5.10	To elect Mr. Wong Kwan Kit as an independent non-executive director of the Fourth Session of the Board and to authorize the Board to fix the remuneration.	133,289,357 (99.459607%)	724,200 (0.540393%)	3,700 (—)
6	To approve the proposal on the election of supervisors for the Fourth Session of the Supervisory Committee.			
6.1	To elect Mr. Liu Yuanzhong as a supervisor of the Fourth Session of the Supervisory Committee and to authorize the Board to fix the remuneration.	133,397,357 (99.540196%)	616,200 (0.459804%)	3,700 (—)

Ordinary Resolutions ⁽¹⁾		Number of Votes (%)		
		For	Against	Abstain ⁽²⁾
6.2	To elect Ms. Yang Qing as a supervisor of the Fourth Session of the Supervisory Committee and to authorize the Board to fix the remuneration.	133,397,357 (99.540196%)	616,200 (0.459804%)	3,700 (—)
6.3	To elect Mr. Tang Yuejun as a supervisor of the Fourth Session of the Supervisory Committee and to authorize the Board to fix the remuneration.	133,397,357 (99.540196%)	616,200 (0.459804%)	3,700 (—)
7	To approve the implementation rules of cumulative voting system.	133,397,357 (99.250473%)	1,007,400 (0.749527%)	3,700 (—)
8	To approve the online voting management system for the shareholders' general meeting.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
9	To approve the proposed amendments to the rules for the management of the related party transactions.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
Special Resolutions ⁽¹⁾		Number of Votes (%)		
		For	Against	Abstain ⁽²⁾
10	To approve the proposal on amending the Draft of Articles of Association of A Shares, the Rules of Procedure of the General Meeting and the Rules of Procedure of the Board of Directors of the Company.			
10.1	The proposed amendments to the Draft of Articles of Association of A Shares.	133,680,557 (99.461180%)	724,200 (0.538820%)	3,700 (—)
10.2	The proposed amendments to the Rules of Procedure of the General Meeting.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)
10.3	The proposed amendments to the Rules of Procedure of Board of Directors.	133,788,557 (99.541534%)	616,200 (0.458466%)	3,700 (—)

Notes:

- (1) The full text of the resolutions are set out in the Notices of AGM.
- (2) In counting the voting results for a resolution, votes of abstention casted and abstention from voting were both not regarded as votes with voting rights.

As more than half of the votes were cast in favour of the ordinary resolutions numbered 1 to 9 set out above at the AGM, all such resolutions were duly passed as ordinary resolutions of the Company. As more than two-thirds of the votes were cast in favour of the special resolutions numbered 10.1 to 10.3 set out above at the AGM, all such resolutions were duly passed as special resolutions of the Company.

RETIREMENT OF THE DIRECTORS OF THE THIRD SESSION OF THE BOARD

The Board further announces that, Mr. Gan Renbao did not offer himself for re-election due to age considerations and Mr. Li Yuanxu did not offer himself for re-election upon considering his tenure as an independent non-executive Director for almost nine years. Due to the election of the new session of the Board, the tenures of Mr. Gan Renbao and Mr. Li Yuanxu, Directors of the Third Session of the Board, have expired and they will no longer serve as Directors or hold any positions in the Board committees in the Company from the date of approval of election of the Fourth Session of the Board at the AGM.

Mr. Gan Renbao and Mr. Li Yuanxu have confirmed that they have no disagreement with the Board and there are no other matters related to their retirements that need to be brought to the attention of the Shareholders. The Board would like to express its sincere gratitude to Mr. Gan Renbao and Mr. Li Yuanxu for their valuable contributions to the Board and the Company during their tenures of service.

APPOINTMENT OF DIRECTORS AND SUPERVISORS

Appointment of Directors for the Fourth Session of the Board

The Company is pleased to announce that Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, Ms. Chen Yiyi and Mr. Tang Minjie were re-elected as executive Directors, Ms. You Jie was re-elected as a non-executive Director, and Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Zhu Qin and Mr. Wong Kwan Kit were re-elected as independent non-executive Directors at the AGM for a term of three years commencing from the date of the AGM.

The biographical details of the Directors listed above were set out in the Circular.

Appointment of Supervisors for the Fourth Session of the Supervisory Committee

The Company is pleased to announce that Mr. Liu Yuanzhong, Ms. Yang Qing and Mr. Tang Yuejun were re-elected at the AGM as supervisors of the Company (“**Supervisors**”) for a term of three years commencing from the date of the AGM.

The biographical details of the Supervisors listed above were set out in the Circular.

Election of Chairman of the Board, Chairman of the Supervisory Committee and Employee Representative Supervisors

The Board is pleased to announce that immediately following the AGM, Dr. Hou Yongtai was unanimously elected by the Board as the Chairman of the Fourth Session of the Board. His term of office would be consistent with the term of office of his directorship.

Also, immediately following the AGM, Mr. Liu Yuanzhong was unanimously elected by the Supervisory Committee as the Chairman of the Fourth Session of the Supervisory Committee of the Company. His term of office would be consistent his term of office as a Supervisor.

The Fourth Session of the Supervisory Committee of the Company comprises five Supervisors, including one shareholder representative Supervisor, namely Mr. Liu Yuanzhong; two independent Supervisors, namely Ms. Yang Qing and Mr. Tang Yuejun; and two employee representative Supervisors, namely Mr. Wei Changzheng and Mr. Yang Linfeng. At the employees' representative conference convened by the Company on June 27, 2019, Mr. Wei Changzheng and Mr. Yang Linfeng were re-elected as the employee representative Supervisors. Their respective term of office was consistent with the term of other Supervisors.

The biographies of Mr. Wei Changzheng and Mr. Yang Linfeng are as follows:

Mr. Wei Changzheng

Mr. Wei Changzheng, aged 39, the employee representative Supervisor of the Company. Mr. Wei has been acting as the deputy manager of the research and development department at Shanghai Haohai Bio Technology Company Limited (“**Haohai Limited**”), the predecessor of the Company, since October 2009, and he has continued to serve this position after the conversion of Haohai Limited into the Company. He has been working as the manager at the department of research and development in Shanghai Qisheng Biologics Company Limited from October 2009 until April 2016, and a director in the department of research and development since April 2016 to present. He has been appointed as a Supervisor since July 2010. Mr. Wei obtained a doctor of science from Ocean University of China (中國海洋大學) in June 2007. He also served as a director of Shanghai Qisheng Medical Technology Development Co., Ltd., a subsidiary of the Company, since April 2018.

Mr. Yang Linfeng

Mr. Yang Linfeng, aged 37, is an employee representative Supervisor of the Company. He has been an associate of the chief human resource officer of the Company from July 2011 to November 2015, and he has been a Performance & Development manager of Human Resource since November 2015. He has been appointed as the Supervisor since September 2014. Mr. Yang obtained a doctor's degree in management at Fudan University in June 2011.

As at the date of this announcement, save as disclosed above and in the Circular, all of the Directors and Supervisors have confirmed that: (i) they are not related to any other Directors, Supervisors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) they did not hold any directorship in any other public companies whose shares were listed in Hong Kong or any overseas stock exchange in the past three years; (iii) none of them have or are deemed to have any interest in the shares or underlying shares of the Company or associated corporations (as defined in Part XV of the Securities and Futures Ordinance); (iv) no other matters are required to be brought to the attention of shareholders of the Company or the Stock Exchange or required to be disclosed under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules.

The above Directors and Supervisors will enter into service agreements with the Company respectively. The remuneration of the Directors and Supervisors will be proposed by the remuneration committee of the Board with reference to the prevailing market rate, the Company's remuneration policy, and their duties with the Group and contribution to the Group, and will be ultimately determined by the Board and a further disclosure will be made by the Company in its interim report or annual report while the terms of the services agreements are finalised.

APPOINTMENT OF MEMBER / CHAIRMAN OF THE BOARD COMMITTEES

The Board is pleased to announce that, with effect from June 27, 2019, Mr. Zhu Qin, an independent non-executive Director of the Company, has been appointed as the chairman of the nomination committee of the Board; Mr. Wong Kwan Kit, an independent non-executive Director of the Company, has been appointed as a member of the nomination committee of the Board and of the audit committee of the Board;

and Mr. Chen Huabin, an independent non-executive Director of the Company, has been appointed as a member of the remuneration committee of the Board and of the strategy committee of the Board. Save as disclosed above, the composition of each Board committee remains unchanged.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, PRC, June 27, 2019

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive director of the Company is Ms. You Jie; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Zhu Qin and Mr. Wong Kwan Kit.

** For identification purpose only*